Table 2.

Sensitivity (%) of PRRSV Ab ELISAs at each sampling point (95% confidence interval)

Study day	0	3	7	10	14
Group V
IDEXX	0 (0–30)	0 (0–30)	0 (0–30)	80 (44–98)	100 (69–100)
INgezim	90 (60–98)	70 (35–93)	100 (69–100)	100 (69–100)	100 (69–100)
HIPRA A/S	20 (3–56)	20 (3–56)	10 (0–45)	50 (19–81)	50 (19–81)
HIPRA E/S	0 (0–30)	0 (0–30)	0 (0–30)	20 (3–56)	20 (3–56)
QIAGEN	0 (0–30)	0 (0–30)	0 (0–30)	80 (44–98)	100 (69–100)
AJ	0 (0–30)	0 (0–30)	20 (3–56)	70 (35–93)	80 (44–98)
Group N
IDEXX	n.d.	0 (0–30)	0 (0–30)	70 (35–93)	90 (60–98)
INgezim	n.d.	0 (0–30)	0 (0–30)	100 (69–100)	100 (69–100)
HIPRA A/S	n.d.	0 (0–30)	0 (0–30)	0 (0–0)	30 (7–65)
HIPRA E/S	n.d.	0 (0–30)	0 (0–30)	0 (0–0)	0 (0–0)
QIAGEN	n.d.	0 (0–30)	0 (0–30)	40 (12–74)	90 (60–98)
AJ	n.d.	0 (0–30)	0 (0–30)	10 (0–45)	60 (26–88)

Group V: vaccination with an inactivated PRRSV type 1 vaccine on days -33 and -19

Groups V and N: intradermal application of an HP PRRSV field strain on day 0

n.d. not done